0.6532

0.40% -0.0026

Outlook Therapeutics Inc (OTLK)

Overview News Price History Financials Discussions Forecast Stock Split

Outlook Therapeutics Inc stock is traded at $0.6532, with a volume of 435.56K. It is down -0.40% in the last 24 hours and up +2.05% over the past month. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Previous Close:

$0.6558

Open:

$0.6551

24h Volume:

435.56K

Relative Volume:

0.03

Market Cap:

$159.02M

Revenue:

$424.90K

Net Income/Loss:

$-94.02M

P/E Ratio:

-0.2629

EPS:

-2.4842

Net Cash Flow:

$-51.25M

1W Performance:

+0.08%

1M Performance:

+2.05%

6M Performance:

+214.01%

1Y Performance:

-32.93%

1-Day Range:

$0.6476

$0.6705

1-Week Range:

$0.6411

$0.7137

52-Week Range:

$0.1611

$2.5375

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name

Outlook Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (595)

Phone

(609) 619-3990

Address

111 S. WOOD AVENUE, ISELIN, NJ

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

OTLK's Discussions on Twitter

Compare OTLK vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OTLK Outlook Therapeutics Inc	0.6532	159.65M	424.90K	-94.02M	-51.25M	-2.4842
VRTX Vertex Pharmaceuticals Inc	521.94	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	789.31	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.11	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.10	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	202.75	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight
Apr-03-23	Initiated	Guggenheim	Buy
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-22	Initiated	BTIG Research	Buy
Sep-13-22	Initiated	Chardan Capital Markets	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
May-16-19	Initiated	Oppenheimer	Outperform
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

Sep 24, 2026

OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - Stocktwits

Sep 24, 2026

Sep 23, 2026

OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits

Sep 23, 2026

Sep 22, 2026

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits

Sep 22, 2026

Sep 20, 2026

Outlook Therapeutics, Inc.(NasdaqCM: OTLK) added to S&P Global BMI Index - marketscreener.com

Sep 20, 2026

Sep 19, 2026

These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits

Sep 19, 2026

Sep 18, 2026